Jinghua Pharmaceutical Group Co., Ltd.

Shenzhen Stock Exchange 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd. Net Income for the year ending December 31, 2023: USD 34.89 M

Jinghua Pharmaceutical Group Co., Ltd. Net Income is USD 34.89 M for the year ending December 31, 2023, a 13.44% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Jinghua Pharmaceutical Group Co., Ltd. Net Income for the year ending December 31, 2022 was USD 30.75 M, a 21.60% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Net Income for the year ending December 31, 2021 was USD 25.29 M, a 491.18% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Net Income for the year ending December 31, 2020 was USD 4.28 M, a 105.68% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Net Income for the year ending December 31, 2019 was USD -75.30 M, a -325.48% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Shenzhen Stock Exchange: 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd.

CEO	Mr. Yunzhong Zhou
IPO Date	Feb. 3, 2010
Location	China
Headquarters	No 2-02#, Xrd Between 3 Haibin Rd & 2 To
Employees	1,493
Sector	Health Care
Industries Pharmaceuticals Petrochemicals

Description

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Nantong, China.

Key trends

Past 5 years